Literature DB >> 19228147

A review of the pharmacokinetic and pharmacological properties of a once-yearly administered histrelin acetate implant in the treatment of prostate cancer.

Peter Schlegel1.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19228147     DOI: 10.1111/j.1464-410X.2009.08383.x

Source DB:  PubMed          Journal:  BJU Int        ISSN: 1464-4096            Impact factor:   5.588


× No keyword cloud information.
  5 in total

Review 1.  Pharmacotherapeutic Targeting of G Protein-Coupled Receptors in Oncology: Examples of Approved Therapies and Emerging Concepts.

Authors:  Rosamaria Lappano; Marcello Maggiolini
Journal:  Drugs       Date:  2017-06       Impact factor: 9.546

Review 2.  Long acting systemic HIV pre-exposure prophylaxis: an examination of the field.

Authors:  William R Lykins; Ellen Luecke; Daniel Johengen; Ariane van der Straten; Tejal A Desai
Journal:  Drug Deliv Transl Res       Date:  2017-12       Impact factor: 4.617

Review 3.  Histrelin: in advanced prostate cancer.

Authors:  Emma D Deeks
Journal:  Drugs       Date:  2010-03-26       Impact factor: 9.546

4.  Long-term efficacy and tolerability of abdominal once-yearly histrelin acetate subcutaneous implants in patients with advanced prostate cancer.

Authors:  Sean Woolen; Cameron Holzmeyer; Emily Nesbitt; Paul F Siami
Journal:  Prostate Cancer       Date:  2014-12-04

5.  Development of a Biodegradable Subcutaneous Implant for Prolonged Drug Delivery Using 3D Printing.

Authors:  Sarah A Stewart; Juan Domínguez-Robles; Victoria J McIlorum; Elena Mancuso; Dimitrios A Lamprou; Ryan F Donnelly; Eneko Larrañeta
Journal:  Pharmaceutics       Date:  2020-01-28       Impact factor: 6.321

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.